Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
出版年份 2022 全文链接
标题
Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia
作者
关键词
-
出版物
European Journal of Preventive Cardiology
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2022-02-15
DOI
10.1093/eurjpc/zwac025
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Advances in familial hypercholesterolaemia in children
- (2021) M Doortje Reijman et al. Lancet Child & Adolescent Health
- Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia
- (2020) G. Kees Hovingh et al. CIRCULATION
- Worldwide Prevalence of Familial Hypercholesterolemia
- (2020) Sabina O. Beheshti et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cognition After Lowering LDL-Cholesterol With Evolocumab
- (2020) Baris Gencer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis
- (2020) Hangying Ying et al. CARDIOVASCULAR DRUGS AND THERAPY
- Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials
- (2018) Jie Bai et al. Journal of Clinical Lipidology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intensive LDL-cholesterol lowering therapy and neurocognitive function
- (2017) Maciej Banach et al. PHARMACOLOGY & THERAPEUTICS
- PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
- (2016) Matthew K. Ito et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
- (2015) Albert Wiegman et al. EUROPEAN HEART JOURNAL
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
- (2013) B. G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Blood sample volumes in child health research: review of safe limits
- (2011) Stephen RC Howie BULLETIN OF THE WORLD HEALTH ORGANIZATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started